Hookipa Pharma (NASDAQ:HOOK) Given New $7.00 Price Target at JMP Securities

Hookipa Pharma (NASDAQ:HOOK) had its target price cut by JMP Securities from $24.00 to $7.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Separately, Royal Bank of Canada decreased their target price on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday, November 15th.

Hookipa Pharma Stock Up 0.9 %

Hookipa Pharma stock traded up $0.02 during midday trading on Thursday, reaching $2.32. The company’s stock had a trading volume of 9,153 shares, compared to its average volume of 57,692. The business has a 50-day simple moving average of $3.90 and a 200-day simple moving average of $5.56. The company has a market cap of $27.98 million, a P/E ratio of -0.62 and a beta of 0.84. Hookipa Pharma has a fifty-two week low of $2.19 and a fifty-two week high of $11.30.

Institutional Investors Weigh In On Hookipa Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of HOOK. Acadian Asset Management LLC grew its holdings in shares of Hookipa Pharma by 85.8% during the first quarter. Acadian Asset Management LLC now owns 882,262 shares of the company’s stock worth $627,000 after purchasing an additional 407,532 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Hookipa Pharma in the 1st quarter valued at about $31,000. Renaissance Technologies LLC boosted its position in shares of Hookipa Pharma by 38.4% in the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the period. Finally, Ikarian Capital LLC purchased a new position in Hookipa Pharma during the 3rd quarter worth approximately $228,000. 63.88% of the stock is owned by hedge funds and other institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.